Nicholas Cozzi

Nicholas Cozzi is a clinical researcher working at the intersection of psychedelic drug development and clinical therapeutics. His published and in‑progress work spans process development for psilocybin manufacture — including direct phosphorylation approaches that enable optimised cGMP kilogram‑scale production — through to translational pharmacology and early‑phase clinical research. Cozzi has contributed to pharmacokinetic characterisations of escalating oral psilocybin doses in healthy adults and to experimental studies assessing subjective effects and tolerability at higher doses.

On the clinical side, Cozzi has been involved in controlled investigations of psilocybin for primary headache disorders, including randomised, double‑blind, placebo‑controlled trials testing low‑dose pulse regimens for cluster headache suppression and exploratory studies of psilocybin's migraine‑suppressing effects. His portfolio reflects a translational focus: enabling reliable drug supply and quality control while designing and executing mechanistic and therapeutic trials to inform clinical utility, dosing strategies and safety profiles of psilocybin in neurological and psychiatric indications.